Breast cancer cells interact with osteoblasts to support osteoclast formation

R. J. Thomas, Theresa Guise, J. J. Yin, J. Elliott, N. J. Horwood, T. J. Martin, M. T. Gillespie

Research output: Contribution to journalArticle

421 Citations (Scopus)

Abstract

Breast cancers commonly cause osteolytic metastases in bone, a process that is dependent upon osteoclast-mediated bone resorption. Recently the osteoclast differentiation factor (ODF), better termed RANKL (receptor activator of NF-κB ligand), expressed by osteoblasts has been cloned as well as its cognate signaling receptor, receptor activator of NFκB (RANK), and a secreted decoy receptor osteoprotegerin (OPG) that limits RANKL's biological action. We determined that the breast cancer cell lines MDA-MB-231, MCF-7, and T47D as well as primary breast cancers do not express RANKL but express OPG and RANK. MCF-7, MDA-MB-231, and T47D cells did not act as surrogate osteoblasts to support osteoclast formation in coculture experiments, a result consistent with the fact that they do not express RANKL. When MCF-7 cells overexpressing PTH-related protein (PTHrP) were added to cocultures of murine osteoblasts and hematopoietic cells, osteoclast formation resulted without the addition of any osteotropic agents; cocultures with MCF-7 or MCF-7 cells transfected with pcDNAIneo required exogenous agents for osteoclast formation. When MCF-7 cells overexpressing PTHrP were cultured with murine osteoblasts, osteoblastic RANKL messenger RNA (mRNA) levels were enhanced and osteoblastic OPG mRNA levels diminished; MCF-7 parental cells had no effect on RANKL or OPG mRNA levels when cultured with osteoblastic cells. Using a murine model of breast cancer metastasis to bone, we established that MCF-7 cells that overexpress PTHrP caused significantly more bone metastases, which were associated with increased osteoclast formation, elevated plasma PTHrP concentrations and hypercalcaemia compared with parental or empty vector controls.

Original languageEnglish (US)
Pages (from-to)4451-4458
Number of pages8
JournalEndocrinology
Volume140
Issue number10
StatePublished - 1999
Externally publishedYes

Fingerprint

MCF-7 Cells
Osteoclasts
Osteoprotegerin
Osteoblasts
Breast Neoplasms
Coculture Techniques
Neoplasm Metastasis
Bone and Bones
Messenger RNA
Proteins
RANK Ligand
Hypercalcemia
Bone Resorption
Ligands
Cell Line

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Thomas, R. J., Guise, T., Yin, J. J., Elliott, J., Horwood, N. J., Martin, T. J., & Gillespie, M. T. (1999). Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology, 140(10), 4451-4458.

Breast cancer cells interact with osteoblasts to support osteoclast formation. / Thomas, R. J.; Guise, Theresa; Yin, J. J.; Elliott, J.; Horwood, N. J.; Martin, T. J.; Gillespie, M. T.

In: Endocrinology, Vol. 140, No. 10, 1999, p. 4451-4458.

Research output: Contribution to journalArticle

Thomas, RJ, Guise, T, Yin, JJ, Elliott, J, Horwood, NJ, Martin, TJ & Gillespie, MT 1999, 'Breast cancer cells interact with osteoblasts to support osteoclast formation', Endocrinology, vol. 140, no. 10, pp. 4451-4458.
Thomas RJ, Guise T, Yin JJ, Elliott J, Horwood NJ, Martin TJ et al. Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology. 1999;140(10):4451-4458.
Thomas, R. J. ; Guise, Theresa ; Yin, J. J. ; Elliott, J. ; Horwood, N. J. ; Martin, T. J. ; Gillespie, M. T. / Breast cancer cells interact with osteoblasts to support osteoclast formation. In: Endocrinology. 1999 ; Vol. 140, No. 10. pp. 4451-4458.
@article{2301d9a46c454f45ba511d5c13258e5c,
title = "Breast cancer cells interact with osteoblasts to support osteoclast formation",
abstract = "Breast cancers commonly cause osteolytic metastases in bone, a process that is dependent upon osteoclast-mediated bone resorption. Recently the osteoclast differentiation factor (ODF), better termed RANKL (receptor activator of NF-κB ligand), expressed by osteoblasts has been cloned as well as its cognate signaling receptor, receptor activator of NFκB (RANK), and a secreted decoy receptor osteoprotegerin (OPG) that limits RANKL's biological action. We determined that the breast cancer cell lines MDA-MB-231, MCF-7, and T47D as well as primary breast cancers do not express RANKL but express OPG and RANK. MCF-7, MDA-MB-231, and T47D cells did not act as surrogate osteoblasts to support osteoclast formation in coculture experiments, a result consistent with the fact that they do not express RANKL. When MCF-7 cells overexpressing PTH-related protein (PTHrP) were added to cocultures of murine osteoblasts and hematopoietic cells, osteoclast formation resulted without the addition of any osteotropic agents; cocultures with MCF-7 or MCF-7 cells transfected with pcDNAIneo required exogenous agents for osteoclast formation. When MCF-7 cells overexpressing PTHrP were cultured with murine osteoblasts, osteoblastic RANKL messenger RNA (mRNA) levels were enhanced and osteoblastic OPG mRNA levels diminished; MCF-7 parental cells had no effect on RANKL or OPG mRNA levels when cultured with osteoblastic cells. Using a murine model of breast cancer metastasis to bone, we established that MCF-7 cells that overexpress PTHrP caused significantly more bone metastases, which were associated with increased osteoclast formation, elevated plasma PTHrP concentrations and hypercalcaemia compared with parental or empty vector controls.",
author = "Thomas, {R. J.} and Theresa Guise and Yin, {J. J.} and J. Elliott and Horwood, {N. J.} and Martin, {T. J.} and Gillespie, {M. T.}",
year = "1999",
language = "English (US)",
volume = "140",
pages = "4451--4458",
journal = "Endocrinology",
issn = "0013-7227",
publisher = "The Endocrine Society",
number = "10",

}

TY - JOUR

T1 - Breast cancer cells interact with osteoblasts to support osteoclast formation

AU - Thomas, R. J.

AU - Guise, Theresa

AU - Yin, J. J.

AU - Elliott, J.

AU - Horwood, N. J.

AU - Martin, T. J.

AU - Gillespie, M. T.

PY - 1999

Y1 - 1999

N2 - Breast cancers commonly cause osteolytic metastases in bone, a process that is dependent upon osteoclast-mediated bone resorption. Recently the osteoclast differentiation factor (ODF), better termed RANKL (receptor activator of NF-κB ligand), expressed by osteoblasts has been cloned as well as its cognate signaling receptor, receptor activator of NFκB (RANK), and a secreted decoy receptor osteoprotegerin (OPG) that limits RANKL's biological action. We determined that the breast cancer cell lines MDA-MB-231, MCF-7, and T47D as well as primary breast cancers do not express RANKL but express OPG and RANK. MCF-7, MDA-MB-231, and T47D cells did not act as surrogate osteoblasts to support osteoclast formation in coculture experiments, a result consistent with the fact that they do not express RANKL. When MCF-7 cells overexpressing PTH-related protein (PTHrP) were added to cocultures of murine osteoblasts and hematopoietic cells, osteoclast formation resulted without the addition of any osteotropic agents; cocultures with MCF-7 or MCF-7 cells transfected with pcDNAIneo required exogenous agents for osteoclast formation. When MCF-7 cells overexpressing PTHrP were cultured with murine osteoblasts, osteoblastic RANKL messenger RNA (mRNA) levels were enhanced and osteoblastic OPG mRNA levels diminished; MCF-7 parental cells had no effect on RANKL or OPG mRNA levels when cultured with osteoblastic cells. Using a murine model of breast cancer metastasis to bone, we established that MCF-7 cells that overexpress PTHrP caused significantly more bone metastases, which were associated with increased osteoclast formation, elevated plasma PTHrP concentrations and hypercalcaemia compared with parental or empty vector controls.

AB - Breast cancers commonly cause osteolytic metastases in bone, a process that is dependent upon osteoclast-mediated bone resorption. Recently the osteoclast differentiation factor (ODF), better termed RANKL (receptor activator of NF-κB ligand), expressed by osteoblasts has been cloned as well as its cognate signaling receptor, receptor activator of NFκB (RANK), and a secreted decoy receptor osteoprotegerin (OPG) that limits RANKL's biological action. We determined that the breast cancer cell lines MDA-MB-231, MCF-7, and T47D as well as primary breast cancers do not express RANKL but express OPG and RANK. MCF-7, MDA-MB-231, and T47D cells did not act as surrogate osteoblasts to support osteoclast formation in coculture experiments, a result consistent with the fact that they do not express RANKL. When MCF-7 cells overexpressing PTH-related protein (PTHrP) were added to cocultures of murine osteoblasts and hematopoietic cells, osteoclast formation resulted without the addition of any osteotropic agents; cocultures with MCF-7 or MCF-7 cells transfected with pcDNAIneo required exogenous agents for osteoclast formation. When MCF-7 cells overexpressing PTHrP were cultured with murine osteoblasts, osteoblastic RANKL messenger RNA (mRNA) levels were enhanced and osteoblastic OPG mRNA levels diminished; MCF-7 parental cells had no effect on RANKL or OPG mRNA levels when cultured with osteoblastic cells. Using a murine model of breast cancer metastasis to bone, we established that MCF-7 cells that overexpress PTHrP caused significantly more bone metastases, which were associated with increased osteoclast formation, elevated plasma PTHrP concentrations and hypercalcaemia compared with parental or empty vector controls.

UR - http://www.scopus.com/inward/record.url?scp=0033305222&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033305222&partnerID=8YFLogxK

M3 - Article

VL - 140

SP - 4451

EP - 4458

JO - Endocrinology

JF - Endocrinology

SN - 0013-7227

IS - 10

ER -